Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1959 1
1980 2
1992 1
1993 2
1994 1
1997 1
1998 1
2000 1
2003 1
2004 1
2005 2
2008 1
2009 4
2010 2
2011 5
2012 3
2013 7
2014 5
2015 6
2016 5
2017 10
2018 4
2019 9
2020 9
2021 7
2022 8
2023 10
2024 6
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

101 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for jorda r
Search for Jodrá R instead (3 results)
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.
Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM; IMPROVE-IT Investigators. Cannon CP, et al. N Engl J Med. 2015 Jun 18;372(25):2387-97. doi: 10.1056/NEJMoa1410489. Epub 2015 Jun 3. N Engl J Med. 2015. PMID: 26039521 Free article. Clinical Trial.
How selective are clinical CDK4/6 inhibitors?
Hendrychová D, Jorda R, Kryštof V. Hendrychová D, et al. Among authors: jorda r. Med Res Rev. 2021 May;41(3):1578-1598. doi: 10.1002/med.21769. Epub 2020 Dec 10. Med Res Rev. 2021. PMID: 33300617 Review.
Clinical outcomes after CPX-351 in patients with high-risk acute myeloid leukemia: A comparison with a matched cohort from the Spanish PETHEMA registry.
Bernal T, Moreno AF, de LaIglesia A, Benavente C, García-Noblejas A, Belmonte DG, Riaza R, Salamero O, Foncillas MA, Roldán A, Concepción VN, González LL, Bergua Burgués JM, Lorente de Uña S, Rodríguez-Macías G, de la Fuente Burguera A, García Pérez MJ, López-Lorenzo JL, Martínez P, Aláez C, Callejas M, Martínez-Chamorro C, Roca JR, Barciela LA, Mena Durán AV, Gómez Correcha K, Lavilla Rubira E, Amigo ML, Vall-Llovera F, Garrido A, García-Fortes M, de Miguel Llorente D, Leonardo AA, Cervero C, Jordá RC, Pérez-Encinas MM, Zarzuela MP, Figuera A, Rad G, Martínez-Cuadrón D, Montesinos P. Bernal T, et al. Among authors: jorda rc. Cancer Med. 2023 Jul;12(14):14892-14901. doi: 10.1002/cam4.6120. Epub 2023 May 22. Cancer Med. 2023. PMID: 37212507 Free PMC article.
Cyclin dependent kinase 4/6 inhibitor palbociclib synergizes with BCL2 inhibitor venetoclax in experimental models of mantle cell lymphoma without RB1 deletion.
Malarikova D, Jorda R, Kupcova K, Senavova J, Dolnikova A, Pokorna E, Kazantsev D, Nozickova K, Sovilj D, Bellanger C, Chiron D, Andera L, Krystof V, Strnad M, Helman K, Klanova M, Trneny M, Havranek O, Klener P. Malarikova D, et al. Among authors: jorda r. Exp Hematol Oncol. 2024 Mar 25;13(1):34. doi: 10.1186/s40164-024-00499-2. Exp Hematol Oncol. 2024. PMID: 38528594 Free PMC article.
Novel arylazopyrazole inhibitors of cyclin-dependent kinases.
Jorda R, Schütznerová E, Cankař P, Brychtová V, Navrátilová J, Kryštof V. Jorda R, et al. Bioorg Med Chem. 2015 May 1;23(9):1975-81. doi: 10.1016/j.bmc.2015.03.025. Epub 2015 Mar 14. Bioorg Med Chem. 2015. PMID: 25835357
101 results